Introduction to Abirapro 250mg Tablet 30s

Zytiga 250mg Tablet is affiliated with a category of medications known as antineoplastic agents. It comes into action for males in the management of prostate cancer. 

Its mechanism involves hampering the impact of male hormones like testosterone, thereby inhibiting the proliferation and dissemination of cancer cells.

Consume it in the prescribed dosage and time span as suggested by the medical practitioner.

Benefits Of Abirapro 250mg Tablet 30s

  • It slows or stops the growth of cancer cells by lowering testosterone levels in men.

Side Effects Of Abirapro 250mg Tablet 30s

  • Edema (swelling)
  • Vomiting
  • Decreased potassium level in blood
  • Decreased white blood cell count
  • Fatigue
  • Increased liver enzymes
  • Anemia (low number of red blood cells)
  • Urinary tract infection
  • Diarrhea
  • High blood pressure
  • Cough
  • Hypercholesterolemia (high cholesterol)
  • Joint swelling
  • Increased levels of blood fat
  • Altered blood sugar level

Similar Medicine Of Abirapro 250mg Tablet 30s

For information purposes only. Consult a doctor before taking any medicines.

Abatitor 250mg Tablet 120s

Torrent Pharmaceuticals Ltd

Zelgor 250mg Tablet

Sun Pharmaceutical Industries Ltd

Abirapro 250mg Tablet 120s

Glenmark Pharmaceuticals Ltd

Arbitus 250mg Tablet 120s

Dr Reddy s Laboratories Ltd

Abirapro 250mg Tablet 60s

Glenmark Pharmaceuticals Ltd

Abiratas 250mg Tablet 30s

Intas Pharmaceuticals Ltd

Bdron 250mg Tablet 120s

BDR Pharmaceuticals Internationals Pvt

Abitate U Tablet

RPG Life Sciences Ltd

Disease Explanation

Prostate cancer is a prevalent malignancy characterized by the abnormal growth of cells in the prostate gland. Diagnosed through screenings like prostate-specific antigen (PSA) tests and biopsies, this cancer primarily affects older men. Treatment options vary and may include surgery, radiation therapy, hormone therapy, or active surveillance. Early detection is crucial for effective intervention, and discussions with healthcare professionals guide personalized management plans for individuals diagnosed with prostate cancer.

Update on: Monday, 11 March, 2024

Written By:

Written By: